Target
PARP2
6 products, 14 indications
Indications
Ovarian Cancer (2 products)
metastatic non-small cell lung cancer (1 products)
Unresectable stage III non-small cell lung cancer (1 products)
Stage IIIA NSCLC (1 products)
Early stage epithelial ovarian cancer (1 products)
glioblastoma (1 products)
advanced non-squamous NSCLC (1 products)
Metastatic castrate-resistant prostate cancer, Advanced endometrial cancer (1 products)
Metastatic Castration-Resistant Prostate Cancer (1 products)
ovarian cancer (1 products)
Platinum-sensitive recurrent ovarian carcinoma (1 products)
high grade serous ovarian cancer, triple negative breast cancer (1 products)
recurrent advanced ovarian cancer (1 products)
Advanced or recurrent ovarian cancer (1 products)
Loading...
2 drugs
22 abstracts
Abstract
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,
Abstract
Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial.Org: Ivy Brain Tumor Center at Barrow Neurological Institute, Ivy Brain Tumor Center,
Abstract
A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.Org: AdventHealth Cancer Institute, START Mountain Region, Sarah Cannon Research Institute at HealthONE, Sarah Cannon Research Institute/Tennessee Oncology, START San Antonio,
Abstract
Study on the efficacy and toxicity of pamiparib combined with tamoxifen in the treatment of patients with epithelial ovarian cancer with biochemical recurrence during first-line PARPi maintenance therapy.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,
Abstract
Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.Org: Minnesota Oncology, Maplewood, MN, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, FirstHealth Moore Regional Hospital, Pinehurst, NC, Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,
Abstract
Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.Org: Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain, Laboratory of Translational Oncology, Program in Solid Tumors, Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra CCUN, Navarra Institute for Health Research IdISNA, Department of Pathology, Anatomy & Physiology, Navarra University, Pamplona, Spain,
Abstract
Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting.Org: Cleveland Clinic Brunswick Urgent Care, Center for Immunotherapy and Precision Immuno-Oncology,
Abstract
PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Dissecting small cell lung cancer subtypes with cell-free DNA fragmentomes.Org: Delfi Diagnostics, Inc., National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Institute, Vilnius, Lithuania, DELFI Diagnostics, The Johns Hopkins University School of Medicine,
Abstract
The somatic mutation profile of breast cancer in Uganda.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Uganda Cancer Institute (Uganda), Department of Laboratory Medicine and Pathology, University of Washington, Hutchinson Centre Research Institute, Uganda Cancer Institute,
Abstract
A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.Org: Ivy Brain Tumor Center, Phoenix, AZ,
Abstract
Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.Org: Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands Cancer Institute, Leiden University Medical Center, Leiden University,
Abstract
An in-house testing for detection of homologous recombination repair deficiency (HRD) in patients with solid tumors.Org: Department of Gastrointestinal Surgery, Hengyang Central Hospital, Hengyang, China, Quanzhou First Hospital.Fujian, Quanzhou, China, Department of Anesthesiology,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, HaploX Biotechnology Co., Ltd., Shenzhen, China, HaploX Biotechnology, Shenzhen, China,
Abstract
Trends in the use of maintenance therapy in ovarian cancer.Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Health Services Research Department, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Identification of novel actionable SNVs using targeted comprehensive genome profiling in patients with sarcoma.Org: OneCell Dx, Pune, Indiana University – Purdue University Indianapolis, Indx Technology, Cupertino, CA,
Abstract
The application of a multigene NGS assay in homologous recombination deficiency tracking.Org: Genekor, Genekor Medical S.A., Genekor Medical SA, Bioclinic Thessaloniki, National Kapodistrian University of Athens,
Abstract
Clinical features of long-term survivors with advanced high-grade serous ovarian cancer.Org: Medical Oncology Group, Catalan Institute of Oncology and Girona Biomedical Research Institute, Medical School University of Girona, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology-Hospitalet,
Abstract
Learned lessons from a US-wide outreach program to broaden enrollment to the PROMISE Registry, a prostate cancer genetic registry.Org: The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, Fred Hutchinson Cancer Center, Seattle, WA, Virginia Oncology Associates, Hampton, VA, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, Allegheny Health Network Cancer Institute, Pittsburgh, PA, University of California San Diego, La Jolla, CA, Dana-Farber Cancer Institute, Boston, MA, Indiana University Health Arnett Cancer Center, Lafayette, IN, University at Buffalo, Buffalo, NY, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Oregon Health and Science University Knight Cancer Institute, Portland, OR, University of Chicago, Chicago, IL,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
How to close the care gap: Factors hindering the use of BRCA mutation profiling of patients with breast cancer and ovarian cancer in a real world setting.Org: MVR Cancer Centre & Research Institute,
Abstract
Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.Org: CHRU Besançon Hôpital J.Minjoz, Besançon, France, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, Montreal, QC, Canada, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, Department of Urology, Keio University School of Medicine, Tokyo, Japan, Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil,
Drug
VeliparibDrug
rucaparib